Biolevox(TM) intraarticular injections

Products

Information

Biolevox(TM) HA 2.2% is a hyaluronic acid (HA) gel designed for a three intra-articular injection into the osteoarthritis (OA) affected in order to ameliorate symptoms of the osteoarthritis (OA) in synovial joint.Designed HA-based gel contains 44 mg of hyaluronate in 2 mL pre-filled syringe. The combination of high concentration of hyaluronate and optimally high molecular weight creates gel characterized with optimally high viscosity and elasticity . With those properties Biolevox(TM) HA 2.2% is an ideal solution for a triple intra-articular injection viscosupplementation therapy.

Distribution Areas

OceaniaNorth America (USA, Canada)AfricaMiddle East Region (e.g. UAE)Central America (e.g. Mexico)East Asia (e.g. China, Japan, Korea)Europe - EU countriesEurope - non EU (e.g. UK, Russia, ex-CIS countries)South America (e.g. Brazil, Colombia)South Asia (e.g. India, Pakistan, Sri Lanka)South East Asia (e.g. Thailand, Philippines, Singapore)

Supplied From

Poland

All categories

Biopharmaceutical ProductsFinished Dosage FormsInjectablesPackaging Materials and EquipmentMedical Devices and Medical PackagingRegenerative MedicineProducts

Main Categories

Biopharmaceutical ProductsFinished Dosage FormsPackaging Materials and Equipment

Biovico Sp. z o.o.Biovico is a biotechnology and pharmaceutical company focused on researching and developing new innovative and rigorously tested products, manufacturing in the highest GMP level quality and providing with comprehensive and holistic solutions to professionals and patients around the world. From inception in 2008 R&D was a clear focus, understanding that the most important and lasting effects can come only through scientific endeavour. Very soon the first HA product Biolevox family was developed and the line continued to grow and expand.

Biolevox(TM) intraarticular injections

Information

Log in